Empfehlung
28,8
Verkaufen
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
58.2
13D-Filing vorhanden
Risikofreier Zins (T-Bills): 3,72% (Stand: 28.02.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
Stammdaten
Unternehmen
| Name | TENAX THERAPEUTICS, INC. |
|---|---|
| Ticker | TENX |
| CIK | 0000034956 |
Branche
| SIC-Code | 2834 |
|---|---|
| Beschreibung | Pharmaceutical Preparations |
Wertpapier
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Titel | TENAX THERAPEUTICS, INC. |
Status
| Zuletzt geprüft | 2026-03-22 10:30:32.728851 |
|---|
Fondsaktivität (letzte 3 Quartale)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-12-09 | Rich Stuart | Director, Officer, Chief Medical Officer | Open Market Purchase | 2,500 | 10.22 | 25,542.00 | +196,6% | |
| 2025-12-09 | Rich Stuart | Director, Officer, Chief Medical Officer | Open Market Purchase | 2,500 | 10.22 | 25,542.00 | +196,6% | |
| 2025-12-08 | Rich Stuart | Director, Officer, Chief Medical Officer | Open Market Purchase | 2,500 | 10.10 | 25,250.50 | +194,4% | |
| 2025-12-08 | Rich Stuart | Director, Officer, Chief Medical Officer | Open Market Purchase | 2,500 | 10.10 | 25,250.50 | +194,4% | |
| 2025-12-04 | Rich Stuart | Director, Officer, Chief Medical Officer | Open Market Purchase | 2,500 | 9.20 | 22,998.00 | +177,0% | |
| 2025-12-04 | Rich Stuart | Director, Officer, Chief Medical Officer | Open Market Purchase | 2,500 | 9.20 | 22,998.00 | +177,0% | |
| 2025-12-03 | Rich Stuart | Director, Officer, Chief Medical Officer | Open Market Purchase | 1,500 | 9.08 | 13,617.90 | +104,8% | |
| 2025-12-03 | Rich Stuart | Director, Officer, Chief Medical Officer | Open Market Purchase | 1,500 | 9.08 | 13,617.90 | +104,8% | |
| 2025-12-02 | Rich Stuart | Director, Officer, Chief Medical Officer | Open Market Purchase | 1,000 | 9.01 | 9,005.90 | +69,3% | |
| 2025-12-02 | Rich Stuart | Director, Officer, Chief Medical Officer | Open Market Purchase | 1,000 | 9.01 | 9,005.90 | +69,3% | |
| 2025-11-20 | Giordano Christopher Thomas | Director, Officer, CEO | Open Market Purchase | 538 | 7.59 | 4,082.72 | +31,4% | |
| 2025-11-20 | Giordano Christopher Thomas | Director, Officer, CEO | Open Market Purchase | 538 | 7.59 | 4,082.72 | +31,4% | |
| 2025-11-19 | Giordano Christopher Thomas | Director, Officer, CEO | Open Market Purchase | 455 | 7.51 | 3,416.64 | +26,3% | |
| 2025-11-19 | Giordano Christopher Thomas | Director, Officer, CEO | Open Market Purchase | 455 | 7.51 | 3,416.64 | +26,3% | |
| 2025-11-18 | Almenoff June Sherie | Director | Open Market Purchase | 1,900 | 7.52 | 14,279.83 | +109,9% | |
| 2025-11-18 | Giordano Christopher Thomas | Director, Officer, CEO | Open Market Purchase | 1,612 | 7.75 | 12,500.42 | +96,2% | |
| 2025-11-18 | Giordano Christopher Thomas | Director, Officer, CEO | Open Market Purchase | 1,612 | 7.75 | 12,500.42 | +96,2% | |
| 2025-11-18 | Almenoff June Sherie | Director | Open Market Purchase | 1,900 | 7.52 | 14,279.83 | +109,9% | |
| 2025-11-18 | Almenoff June Sherie | Director | Open Market Purchase | 1,900 | 7.52 | 14,279.83 | +109,9% | |
| 2025-11-18 | Almenoff June Sherie | Director | Open Market Purchase | 1,900 | 7.52 | 14,279.83 | +109,9% | |
| 2025-11-17 | MCGAULEY THOMAS | Officer, Interim CFO | Open Market Purchase | 2,000 | 7.34 | 14,674.00 | +113,0% | |
| 2025-11-17 | Almenoff June Sherie | Director | Open Market Purchase | 93 | 7.15 | 664.95 | +5,1% | |
| 2025-11-17 | Almenoff June Sherie | Director | Open Market Purchase | 93 | 7.15 | 664.95 | +5,1% | |
| 2025-11-17 | Almenoff June Sherie | Director | Open Market Purchase | 93 | 7.15 | 664.95 | +5,1% | |
| 2025-11-17 | MCGAULEY THOMAS | Officer, Interim CFO | Open Market Purchase | 5,000 | 7.23 | 36,140.00 | +278,2% | |
| 2025-11-17 | MCGAULEY THOMAS | Officer, Interim CFO | Open Market Purchase | 1,000 | 7.35 | 7,350.00 | +56,6% | |
| 2025-11-17 | Almenoff June Sherie | Director | Open Market Purchase | 93 | 7.15 | 664.95 | +5,1% |
Top-Fondshalter (aktuelles Quartal)
Keine Fondsdaten für das aktuelle Quartal vorhanden.